Scott L Burrows

CFO Burrows sells 7,500 shares ($532.9K) at $69.75–$72.06 via scheduled 10b5-1 plan; retains 97,994 shares + 374,857 stock options.

Scott L Burrows, CFO of Spyre Therapeutics, executed 3 separate sales totaling 7,500 shares for $532,936.98 on 2026-06-01 under a pre-arranged 10b5-1 trading plan adopted 2025-11-10. This is a scheduled, non-discretionary transaction. Post-sale, Burrows retains 97,994 shares in non-derivative holdings plus 374,857 shares through stock options, maintaining a substantial position. The sales occurred when SYRE's stock was at $69.75–$72.06 per share, versus the current price of $73.52; the stock has appreciated 6.4% over the prior 30 days and 81.1% over 90 days. Burrows' prior two sales at SYRE (2026-05-01 and 2024-09-03) preceded mixed subsequent returns (30-day gains followed by 90-day losses). The company is unprofitable with $0 revenue and -$69.0M net income in the latest quarter, a fundamental context relevant to evaluating insider positioning.

CFO Scott L Burrows sells 12,500 shares of SYRE at $71.37 on 2026-05-01; holds 97,994 shares post-sale; stock up 42.0% in 30d

Burrows sold 12,500 shares (12.5K shares) at $71.37, reducing his stake by 11.3% from 110,494 to 97,994 shares. The stock is currently trading at $69.42, down 6.8% from its 52-week high of $74.45, yet has surged 42.0% over the past 30 days and 117.1% over 90 days. Within Burrows's cross-ticker track record, his prior sell had a 90-day return of -1.9%, which was well-timed (100.00% well-timed rate across 1 prior sell). At SYRE specifically, his only prior trade was a sell on 2024-09-03 that showed identical 90-day underperformance (-1.9%). The company is unprofitable with -$11,183,000.00 net income in its latest period and zero revenue, but carries a $5.5B market cap. This sale occurs amid exceptional price momentum—the stock is near 52-week highs after a dramatic 117.1% run in 90 days—and represents a material reduction in the CFO's concentrated exposure to a high-growth but cash-burning biotech.

CFO Scott Burrows sold 18,531 shares of SYRE at $28.17; stock now -38.2% from 52-week high amid -62.0% revenue collapse.

CFO Scott L. Burrows sold 18,531 shares at $28.17 on 2024-09-03, reducing his holdings by 13.7% from 134,953 to 116,422 shares. The sale occurred as Spyre Therapeutics faces severe operational headwinds: latest quarter revenue is $0.00, full-year net income was $-38,837,000.00, and annual revenue growth declined 62.0% year-over-year. The stock has retreated 38.2% from its 52-week high of $45.37 to a current price of $28.04, though it has gained 7.7% over the past 30 days. This sale by a top financial officer—the individual responsible for the company's financial planning and disclosure—during a period of collapsing revenues and persistent unprofitability warrants investor attention to whether this reflects emerging concerns about cash runway, operational viability, or capital structure.